Investment Rating - The report maintains an "Overweight" rating for the agriculture, forestry, animal husbandry, and fishery industry [1][46] Core Insights - The profitability of pig farming has shown signs of recovery, with self-breeding pig farming profits turning positive [30] - The industry has slightly underperformed compared to the CSI 300 index, with a decline of 0.72% from January 5 to January 15, 2026, lagging behind the index by approximately 3.34 percentage points [14] - The report highlights the potential for price recovery in pig farming due to seasonal demand, and emphasizes the importance of capacity reduction in the breeding sector [46][48] Industry Performance Overview - The SW agriculture, forestry, animal husbandry, and fishery industry index has a current PB ratio of approximately 2.63, indicating a slight decline in valuation and positioning at about 59.2% of the historical average since 2006 [21] - Among the sub-sectors, animal health, fishery, agricultural product processing, and planting recorded positive returns, with increases of 8.52%, 4.59%, 1.77%, and 0.45% respectively, while feed and breeding sectors saw declines of 0.99% and 2.34% [17][18] Key Industry Data - The average price of external three-breed pigs fluctuated from 12.86 CNY/kg to 12.48 CNY/kg and then rebounded to 12.76 CNY/kg between January 2 and January 15, 2026 [22] - As of January 15, 2026, the average price of corn was 2363.82 CNY/ton and soybean meal was 3184 CNY/ton, both showing a recent increase [27] - The profit for self-breeding pig farming reached 7.39 CNY/head, while the profit for purchased pig farming was 48.35 CNY/head, indicating a shift from loss to profit [30] Company Insights - Key companies to watch include Muyuan Foods (002714), Wens Foodstuff Group (300498), and Shengnong Development (002299), which are positioned well for potential growth in the sector [48][49] - The report notes that the domestic pet market has growth potential, with exports expected to maintain rapid growth, highlighting opportunities in leading domestic companies [48]

Core Viewpoint - The animal health sector experienced a rise of 0.93% on January 16, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4101.91, down 0.26% [1]. - The Shenzhen Component Index closed at 14281.08, down 0.18% [1]. Group 2: Individual Stock Performance - BioShares (600201) led the gains with a closing price of 17.61, up 3.53%, and a trading volume of 480,000 shares, amounting to a transaction value of 840 million yuan [1]. - Other notable performers included: - Huisheng Bio (300871) at 26.03, up 1.36%, with a transaction value of 434 million yuan [1]. - Xianfeng Holdings (002141) at 3.76, up 1.35%, with a transaction value of 8.13 million yuan [1]. - Ruipu Bio (300119) at 20.15, up 0.90%, with a transaction value of 110 million yuan [1]. - Shunlian Bio (688098) at 9.60, up 0.63%, with a transaction value of 40.84 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 112 million yuan from institutional investors, while retail investors experienced a net outflow of 68.65 million yuan [2]. - The capital flow for individual stocks showed: - BioShares had a net inflow of 75.95 million yuan from institutional investors [3]. - Huisheng Bio had a net inflow of 19.63 million yuan from institutional investors [3]. - Xianfeng Holdings had a net inflow of 16.40 million yuan from institutional investors [3].

Market Overview - The animal health sector experienced a decline of 0.16% on January 15, with the driving force leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - The following stocks in the animal health sector showed notable performance: - *ST Lvkang (002868)*: Closed at 37.13, up 5.01% with a trading volume of 32,900 shares and a turnover of 120 million yuan [1] - Jinhe Biology (002688): Closed at 6.34, up 1.28% with a trading volume of 329,000 shares and a turnover of 207 million yuan [1] - Huisheng Biology (300871): Closed at 25.68, up 0.63% with a trading volume of 188,300 shares and a turnover of 489 million yuan [1] - Other stocks like Pulaike (603566) and Ruipu Biology (300119) also showed slight increases [1] Capital Flow Analysis - The animal health sector saw a net outflow of 32.17 million yuan from institutional investors, while retail investors had a net inflow of 44.53 million yuan [2] - The following stocks had significant capital flow: - Jinhe Biology (002688): Net inflow of 13.58 million yuan from institutional investors, but net outflows from retail investors [3] - *ST Lvkang (002868)*: Net inflow of 6.86 million yuan from institutional investors, with outflows from retail investors [3] - Other stocks like Shenglian Biology (688098) and Driving Force (920275) experienced net outflows from both institutional and retail investors [3]

Market Overview - The animal health sector experienced a decline of 0.44% on January 14, with Haili Biological leading the drop [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.39, up 10.65% on a trading volume of 112,300 shares and a turnover of 118 million yuan [1] - Huisheng Biological (code: 300871) closed at 25.52, up 1.84% with a trading volume of 270,100 shares and a turnover of 696 million yuan [1] - Major decliners included: - Haili Biological (code: 603718) closed at 6.55, down 1.65% with a trading volume of 237,400 shares and a turnover of 157 million yuan [2] - Zhongmu Co., Ltd. (code: 600195) closed at 7.92, down 1.61% with a trading volume of 201,400 shares and a turnover of 161 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 140 million yuan from institutional investors, while retail investors experienced a net inflow of 52.14 million yuan [2] - The detailed capital flow for selected stocks showed: - Huisheng Biological had a net inflow of 23.06 million yuan from institutional investors [3] - ST Green Kang (code: 002868) faced a significant net outflow of 5.87 million yuan from institutional investors [3]

Core Viewpoint - The company announced the temporary use of idle raised funds to supplement working capital, with a total amount not exceeding 80 million yuan [1] Group 1 - On September 19, 2025, the company held a meeting to approve the use of up to 80 million yuan of idle raised funds for temporary working capital [1] - The company actually utilized the full amount of 80 million yuan for this purpose [1] - On January 13, 2026, the company fully repaid the funds back to the special account for raised funds and informed the sponsor institution and the sponsor representative [1]

Group 1 - The core business of the company is the production and sales of animal health products [2] - The company's photovoltaic film business was divested in November 2025 [2] - Any new business developments will be disclosed in accordance with relevant regulations [2]

Core Insights - The animal health sector experienced a rise of 1.09% on January 13, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Stock Performance - Huisheng Biological (300871) closed at 25.06, up 8.39%, with a trading volume of 276,700 shares and a transaction value of 700 million [1] - Other notable performers included: - Qudongli (920275) at 65.6, up 3.99% [1] - Haili Biological (603718) at 6.66, up 1.99% [1] - Xianfeng Holdings (002141) at 3.77, up 1.34% [1] - Shunlian Biological (688098) at 9.78, up 1.03% [1] Capital Flow - The animal health sector saw a net inflow of 34.99 million from institutional investors, while retail investors contributed a net inflow of 30.94 million [2] - However, speculative funds experienced a net outflow of 65.94 million [2] Individual Stock Capital Flow - Major net inflows were observed in: - Biological Shares (600201) with a net inflow of 39.54 million [3] - Jinhe Biological (002688) with a net inflow of 13.45 million [3] - Xianfeng Holdings (002141) with a net inflow of 10.20 million [3] - Conversely, significant net outflows were noted in: - Biological Shares (600201) with a net outflow of 48.25 million from speculative funds [3] - Jinhe Biological (002688) with a net outflow of 1.46 million from retail investors [3]

Summary of Zoetis Conference Call Company Overview - **Company**: Zoetis - **Industry**: Animal Health - **Current Market Size**: Approximately $50 billion, projected to grow to $90 billion over the next 10 years [4][3] Key Industry Insights - **Growth Drivers**: - Strong sectoral tailwinds in both companion animal and livestock segments [3] - Increasing global population demanding nutritious protein [4] - Shift towards pet medicalization driven by younger pet owners (Millennials and Gen Z) [6] - **Market Trends**: - Companion animal market growth driven by increased spending on veterinary care and advanced therapies [6] - Livestock sector recovering from disruptions caused by African swine fever and COVID-19, with mid-single-digit growth [8] Company Performance - **Revenue Growth**: - Zoetis has achieved an 8% compound annual growth rate (CAGR) since its IPO, outperforming the industry average of 5% [5] - **Profitability**: - EBITDA margins of 41%-42% and mid-20s return on invested capital (ROIC) [21] - **R&D Investment**: - $5 billion invested in R&D since IPO, leading to 2,000 regulatory approvals over the last decade [9][10] Product Pipeline and Innovation - **Future Blockbusters**: - 12 potential blockbuster drugs in the pipeline, with expectations for major market approvals annually [11][12] - **Key Areas of Focus**: - Chronic kidney disease, oncology, cardiology, obesity, and anxiety in pets, with significant market potential [13][14][15][16] - **Diagnostics and Preventatives**: - Emphasis on expanding diagnostics and preventative care in livestock and companion animals [20] Market Position and Strategy - **Commercial Excellence**: - Direct field force in 45 markets, combining sales with medical affairs and marketing for effective execution [15] - **Product Leadership**: - Simparica Trio leading in the parasiticide space, with high customer satisfaction [16] - **Dermatology Portfolio**: - Strong portfolio including Apoquel and Cytopoint, with plans for long-acting products [17][18] Financial Strategy - **Capital Allocation**: - Focus on innovation, disciplined capital allocation, and returning excess cash to shareholders through dividends and buybacks [24][25] - **Shareholder Returns**: - Over 125% of free cash flow returned to shareholders in the last three years, with a 13% CAGR in dividends [24] Challenges and Outlook - **Short-term Headwinds**: - Anticipated slowdown in companion animal growth due to price increases and macroeconomic factors [27][29] - **Long-term Confidence**: - Sustained growth expected from livestock and diagnostics, with a focus on executing commercial strategies [30][32] - **Future Growth Projections**: - Long-term growth expectations remain robust, supported by industry trends and Zoetis's innovation pipeline [35] Conclusion - **Zoetis's Position**: - Well-positioned to capitalize on the growing animal health market with a strong pipeline, innovative products, and a disciplined approach to capital allocation [26]

Financial Data and Key Metrics Changes - The company reported product sales for Q4 2025 at $7.6 million, a decrease of 1.6% compared to Q4 2024, with domestic sales growing 8.7% to $7 million [11][12] - Full-year product sales for 2025 totaled $27.6 million, reflecting a 4.3% increase compared to 2024 [12] - The company experienced a significant decline in international sales, particularly in Canada, which dropped 52.6% year-over-year in Q4 [12] Business Line Data and Key Metrics Changes - The First Defense product line saw a notable shift towards Tri-Shield, indicating a migration from Dual-Force products and attracting new dairy and beef customers [12] - Manufacturing output for the key bottleneck process, lyophilization, increased by more than 15% in 2025, with expectations for similar growth in 2026 [8][17] Market Data and Key Metrics Changes - The newborn calf market has evolved, with calf values increasing significantly, now worth approximately $1,300 on day one of life compared to roughly $200 in 2003, raising the economic stakes for early-life calf health [7] - The total addressable market for scour protection is estimated to be around $900 million worldwide [7] Company Strategy and Development Direction - The company is shifting its strategic focus to First Defense, pausing investment in Re-Tain due to an Incomplete Letter from the FDA regarding its new animal drug application [4][6] - The strategy includes expanding the sales team by 50% and creating two new U.S. sales territories to drive growth [16] - The company aims to repurpose manufacturing assets from Re-Tain to support First Defense, enhancing operational efficiency [10][14] Management's Comments on Operating Environment and Future Outlook - Management expressed high confidence in the future sales and profit growth potential of the First Defense business, justifying the strategic shift [5][6] - The company is focused on operational excellence to ensure consistent supply and quality of products, with plans to optimize manufacturing processes [16][17] Other Important Information - A non-cash impairment write-down of approximately $2.9 million is expected due to the shift in strategy regarding Re-Tain [14] - An estimated write-down of $600,000 was taken for inventory deemed unsuitable for requirements [15] Q&A Session Summary Question: Impact of regional pathogens on foreign sales development - Management acknowledged the complexity of international sales and the need for expertise in launching products in different markets, highlighting the importance of hiring experienced personnel [20] Question: Explanation for contract manufacturer's failure to comply with FDA requirements - Management declined to provide details but confirmed that the Incomplete Letter was solely due to issues with the contract manufacturer [22][23] Question: Realism of securing a strategic partner for Re-Tain - Management expressed confidence in the product's capabilities and the need to find the best go-to-market strategy post-investigational studies [27] Question: Timeline for hiring new sales team members - Management confirmed that hiring processes for new sales team members are underway, with expectations to complete them within the current quarter [31] Question: Future cash needs and potential share dilution - Management indicated that various funding options are available, including operating cash flow, loans, and capital raises, but declined to comment on specific plans [33] Question: Clarity on self-imposed milk discard period for Re-Tain - Management explained that the discard period is necessary to avoid impacting cheese manufacturing processes, but it remains less than competitors' requirements [44][45] Question: Explanation for exceeding sales expectations - Management attributed the sales exceeding expectations to effective management practices and a strong commercial team, despite complexities from previous backorder situations [49][50]

Core Viewpoint - The animal health sector experienced a rise of 1.55% on January 9, with significant contributions from leading stocks like Biological Shares, which surged by 4.76% [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4120.43, up by 0.92%, while the Shenzhen Component Index closed at 14120.15, up by 1.15% [1]. - The top-performing stock in the animal health sector was Biological Shares (600201), closing at 17.40 with a gain of 4.76% and a trading volume of 683,900 shares, amounting to a transaction value of 1.179 billion yuan [1]. Group 2: Stock Performance Summary - Other notable stocks included: - Shunlian Biological (688098) at 9.67, up by 1.90% with a trading volume of 64,900 shares [1]. - Zhongmu Shares (600195) at 8.10, up by 1.25% with a trading volume of 138,100 shares [1]. - Ruipu Biological (300119) at 19.90, up by 1.12% with a trading volume of 154,700 shares [1]. - Haili Biological (603718) at 6.48, up by 0.78% with a trading volume of 124,600 shares [1]. Group 3: Capital Flow Analysis - The animal health sector saw a net outflow of 27.3879 million yuan from institutional investors, while retail investors contributed a net inflow of 90.8993 million yuan [2]. - The capital flow for specific stocks showed: - Haili Biological had a net inflow of 10.2913 million yuan from institutional investors [3]. - Jinhe Biological experienced a net inflow of 2.8449 million yuan from institutional investors [3]. - *ST Green Kang (002868) had a net inflow of 1.8780 million yuan from institutional investors [3].